Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.57 |
| ▸ | MGAM | O43451 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295562 | 1.00 | LMNA (0.62) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL11333429 | 0.92 | LMNA (0.72) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL11333427 | 0.92 | LMNA (0.72) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17295314 | 0.88 | MGAM (0.56) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17295313 | 0.88 | MGAM (0.56) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17295612 | 0.88 | LMNA (0.75) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17295616 | 0.88 | LMNA (0.75) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17302214 | 0.82 | CA9 (0.50) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL19096516 | 0.82 | CA9 (0.58) | LMNAHPGDSMN1; SMN2FAAHCA9 | |
| SCHEMBL17302233 | 0.79 | CA9 (0.68) | LMNAHPGDSMN1; SMN2FAAHCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011879-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2022-06-15 | — | — | EP | disclosed |
| EP-3148990-B1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2018-12-18 | — | — | US | disclosed |
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3148990-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181337-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | LMNA 4277/4885HPGD 1946/4885SMN1; SMN2 3070/4885 |
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | LMNA 4207/4885HPGD 1206/4885SMN1; SMN2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.